A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ranexa mechanism of action





Ranexa (Ranolazine) Drug Information Clinical Pharmacology

10/26/2014
08:36 | Author: Devin Garcia

Mechanism of action definition
Ranexa (Ranolazine) Drug Information Clinical Pharmacology

Learn about clinical pharmacology for the drug Ranexa (Ranolazine). The mechanism of action of ranolazine's antianginal effects has not been determined.

Ranolazine is also a substrate of P- glycoprotein. In vitro data indicate that ranolazine is a substrate of CYP3A and, to a lesser degree, of CYP2D6.

These doses in rats and rabbits were associated with an increased maternal mortality rate. Reduced ossification of sternebrae was observed in fetuses of pregnant rabbits dosed at 150 mg/kg/day (1.5 times the MRHD on a surface area basis). There was an increased incidence of misshapen sternebrae and reduced ossification of pelvic and cranial bones in fetuses of pregnant rats dosed at 400 mg/kg/day (2 times the MRHD on a surface area basis).

The pharmacokinetics of ranolazine is unaffected by age, gender, or food.

Comments (1)Read more



Ranolazine - Wikipedia, the free encyclopedia

12/25/2014
06:12 | Author: Caitlin White

Mechanism of action definition
Ranolazine - Wikipedia, the free encyclopedia

Ranolazine, sold under the trade name Ranexa by Gilead Sciences (who acquired It would seem – from the mechanism of action – that ranolazine may be of.

Ranolazine's effect on the QT interval is increased in the setting of liver dysfunction; thus it is contraindicated in persons with mild to severe liver disease.

While the mean increase in the corrected QT interval (QTc) is approximay 6 ms, about 5% of individuals may have QTc prolongations of 15 ms or longer. Ranolazine is known to increase the QT interval on the electrocardiogram.

Ranolazine is metabolized in the liver, particularly by one of the cytochrome CYP3A enzymes, a member of the cytochrome P450 system.

The applicant for this medicinal product is CV Therapeutics Europe Limited.

Comments (2)Read more

Ranexa - FDA prescribing information, side effects and uses

10/24/2014
04:32 | Author: Evan Martin

Mechanism
Ranexa - FDA prescribing information, side effects and uses

Ranexa official prescribing information for healthcare professionals. The mechanism of action of ranolazine's antianginal effects has not been determined.

Ranolazine blocks I Kr and prolongs the QTc interval in a dose-related manner.

Ranexa is indicated for the treatment of chronic angina.

This increase was not enough to account for the 3-fold increase in QT prolongation seen in cirrhotic patients with mild to moderate hepatic impairment. Ranexa is contraindicated in patients with liver cirrhosis. In a study of cirrhotic patients, the C max of ranolazine was increased 30% in cirrhotic patients with mild (Child-Pugh Class A) hepatic impairment, but increased 80% in cirrhotic patients with moderate (Child-Pugh Class B) hepatic impairment compared to patients without hepatic impairment.

Ranexa should be used during pregnancy only when the potential benefit to the patient justifies the potential risk to the fetus.

Comments (3)Read more

Ranexa (ranolazine) HCP Effect

8/23/2014
02:04 | Author: Evan Martin

Gabapentin side effects
Ranexa (ranolazine) HCP Effect

The mechanism of action of ranolazine's antianginal effects has not been determined. Ranexa at therapeutic levels can inhibit the cardiac late sodium current.

Fill out the fields below to send this Web page to a colleague. * required item.

Combination Assessment of Ranolazine In Stable Angina (CARISA) trial description 2.

Gilead Sciences, Inc. You are now leaving the Ranexa website. provides these links as a convenience; however, Gilead does not control, review, or endorse third-party websites, and is not responsible for the content of the website you are about to enter.

2014 Gilead Sciences, Inc. RANP0084 2/14. or its related companies. Gilead, the Gilead logo, and Ranexa are registered trademarks of Gilead Sciences, Inc.

View Ranexa (ranolazine) full Prescribing Information.

‡ The dose of Ranexa should be limited to 500 mg twice daily in patients on diltiazem and other moderate CYP3A inhibitors. † 750 mg BID is not an approved Ranexa dose.

Patients in CARISA received Ranexa or placebo plus standard doses of atenolol, amlodipine, or diltiazem,* as well as short-acting nitrates 2.

*Limit the dose of Ranexa to 500 mg twice daily when coadministered with diltiazem, verapamil, or other moderate CYP3A inhibitors.

This site is intended for US healthcare professionals only.

Please see trial description below.

You are now leaving.

Comments (0)

Ranexa39s mechanism of action added to drug label Drug Topics

6/22/2014
12:20 | Author: Caitlin White

Mechanism
Ranexa39s mechanism of action added to drug label Drug Topics

New information that helps elucidate the mechanism of action of ranolazine extended-release tablets ( Ranexa, CV Therapeutics) has been.

Please send any technical comments or questions to our webmaster.

SUBSCRIBE: Digital / Print / eNewsletter CONNECT: 2008 Marketing Calendar.

To see more Daily News articles, click here.

DEA hits third Cardinal Health distribution c.

To go to the Drug Topics homepage, click here. More More More View Results CONNECT:.

Ranolazine is currently indicated for the treatment of chronic angina in patients who have not achieved adequate response with other antianginal medications, and should be used in combination with amlodipine, beta-blockers, or nitrates. This inhibition has been shown to improve the mechanical and electrical function of the heart. Without inhibition, excess sodium can lead to a subsequent overload of calcium that interferes with proper contraction and relaxation of the organ. New information that helps elucidate the mechanism of action of ranolazine extended-release tablets ( Ranexa, CV Therapeutics) has been added to the drug's prescribing information. Published data suggest that the medication works by inhibition of the excess sodium that flows into cardiac cells through sodium channels during an ischemic event.

Comments (0)